Background Atypical teratoid/rhabdoid tumors (ATRTs) are known to exhibit molecular and
clinical heterogeneity even though SMARCB1 inactivation is the sole recurrent genetic event …

Defects in chromatin modifiers and remodelers have been described both for hematological
and solid malignancies, corroborating and strengthening the role of epigenetic aberrations …

Introduction Highly aggressive thoracic neoplasms characterized by SMARCA4 (BRG1)
deficiency and undifferentiated round cell or rhabdoid morphology have been recently …

Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants.
Although the prognosis of ATRT patients is poor, some patients respond favorably to current …

While investigating cohorts of unclassified sarcomas by RNA sequencing, we identified 19
cases with inactivation of SMARCA4, which encodes an ATPase subunit of BAF chromatin …

PURPOSE Atypical teratoid/rhabdoid tumor (AT/RT) is an aggressive, early-childhood brain
tumor without standard effective treatment. To our knowledge, we conducted the first AT/RT …

We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two
transcriptional subtypes with different clinical outcomes; however, the mechanisms …

Atypical teratoid/rhabdoid tumor (AT/RT) is the most common malignant CNS tumor of
children below 6 months of age. The majority of AT/RTs demonstrate genomic alterations in …

The chromatin remodeler SMARCA4/BRG1 is a key epigenetic regulator with diverse roles
in coordinating the molecular programs that underlie brain tumour development. BRG1 …

Background Controversy exists as to what may be defined as standard of care (including
markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The …